FHM Strategic Financial Impact - South Africa (2026)

FHM Strategic Financial Impact - South Africa

Region: South Africa | Currency: ZAR | Time Horizon: 2026 - 2036
R 19.50
Exch. Rate (ZAR/EUR)
10
Tests per Patient Screening
100k - 2M
Scale of Tests (Volume)
1. The "Scale Dividend": Total Spend vs Test Volume

Benchmarks (Per Patient - 10 Test Protocol):
• Manual (Red): R655.00 fixed cost. Includes "DNA Tax" (15% No-Shows) & Admin Time.
• FHM Digital (Green): Retail Pricing (€2.20 down to €1.54) + R87.50 Ops Cost.
• Scale Logic: Savings generated by eliminating Manual Waste + SaaS Volume Discounts.

2. Margin Analysis: Net Cost Reduction %

Efficiency Gain (Operational Reality Model):
• Pilot (100k): ~17% Saving (Immediate Operational Gain)
• Enterprise (1.5M+): ~48% Saving (Optimization at Scale)

The "Inflation Hedge" (10-Year View)
Scenario: 50,000 Employees (500,000 Tests/Year)
10.0%
SA Medical Inflation
3.0%
EU Tech Inflation
R 150M+
10-Year Cash Preservation
3. 10-Year Forecast: Manual vs Digital

Forecast Logic:
• Manual Model: Compounding at 10% (CPI + 4%).
• FHM Model: Split Growth. Local Ops (Nurse/Care) grows at 10%. Tech Fees grow at 3% (EU) + 5% (FX drift).